Urogenital pelvic malignancy

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

Retrieved on: 
Wednesday, September 21, 2022
Safety, Bevacizumab, Memory, Engineering, Woman, CI, Recurrence, Ovarian cancer, Vaccinia, Vagina, Company, Medicine, United, Clinical Ovarian Cancer & Other Gynecologic Malignancies, GOG, SEER, Immunotherapy, Survival, Vulva, Patient, Cancer, NCI, Clinical Oncology, CEO, Urogenital pelvic malignancy, ORR, Progression-free survival, Uterus, Neoplasm, Method, Death, Research, Abdominal pain, GLOBE, DNA, Disease, RECIST, Immunogenic cell death, Pharmaceutical industry, Birth control, Vaccine, Genelux Corporation, Gynecologic Oncology (journal), Epidemiology

Initiating the OnPrime trial represents a major milestone for Genelux, saidThomas D. Zindrick, President and CEO, Genelux.

Key Points: 
  • Initiating the OnPrime trial represents a major milestone for Genelux, saidThomas D. Zindrick, President and CEO, Genelux.
  • Our goal in Phase 3 is to replicate these positive results and transform the treatment paradigm for this particularly difficult-to-treat cancer.
  • We look forward to progressing our study and sharing updates on the Olvi-Vec clinical development program.
  • Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer.

VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility

Retrieved on: 
Monday, August 30, 2021
PFS, Ovarian cancer, Annual report, Ovary, Glioblastoma, Twitter, Blood, Paclitaxel, OS, Ofranergene obadenovec, Cancer, Radiation, U.S. Securities and Exchange Commission, GLOBE, Family, Survival, SEC, CMC, OVAL, Research, Food, Platinum, TEL, Form 20-F, Therapy, Marie Cassidy, GOG, VBL, Urogenital pelvic malignancy, Clinical Ovarian Cancer & Other Gynecologic Malignancies, NASDAQ, Adult, Risk, Patient, European Commission, Documentation, LinkedIn, Nursing, YouTube, FDA, BLA, Woman, Uterus, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

VBL prepared and submitted the requested data and documentation to the FDA in early August and the FDA has now provided clearance for VBL to use new batches of VB-111 produced in its commercial-scale facility located in Modiin, Israel.

Key Points: 
  • VBL prepared and submitted the requested data and documentation to the FDA in early August and the FDA has now provided clearance for VBL to use new batches of VB-111 produced in its commercial-scale facility located in Modiin, Israel.
  • VBL has sufficient FDA-cleared batches and will resume patient recruitment in the OVAL trial in the United States.
  • The OVAL trial evaluating VB-111 in ovarian cancer is planned to enroll approximately 400 patients globally and nearly 80% of patients have already been recruited.
  • To learn more about VBL Therapeutics, please visit vblrx.com or follow the company on LinkedIn , Twitter , YouTube or Facebook .